News Announcements

Launch of the Butterfly-compatible Focalist™ system advances software-defined imaging for robotic intervention, while marking the first Butterfly Embedded™ partner technology to reach the market.

‍BURLINGTON, Mass. & SAN MATEO, Calif. — October 1, 2026 — Mendaera, Inc., a healthcare technology company building robotics and intelligence for procedural medicine, and Butterfly Network, Inc. (NYSE: BFLY), a pioneer and leader in semiconductor-based ultrasound, programmable cloud software and AI, today announced that Mendaera’s Focalist™ system is now commercially available with Butterfly Network’s Ultrasound-on-Chip™ imaging technology.  

Mendaera’s FDA-cleared Focalist system combines handheld robotics, real-time imaging, and intelligent guidance software to support precision, confidence, and consistency during image-guided needle procedures, including vascular access, regional nerve blocks, and organ access. 

“Ultrasound is fundamental to how Focalist sees and guides intervention, and Butterfly gives us a uniquely digital and programmable imaging platform to build on,” said Josh DeFonzo, Co-Founder and CEO of Mendaera. “Bringing Butterfly into our commercial platform expands access to precise, image-guided intervention today, while its software-defined architecture opens a path toward AI-enabled image interpretation and robotic action.”

Butterfly and Mendaera first announced their collaboration through the Butterfly Embedded™ program, bringing together complementary imaging and robotics technologies with the shared goal of advancing digitally native, AI-enabled intervention. 

“Mendaera is tackling a real problem in healthcare with a platform designed to expand access to procedural imaging, while reducing reliance on a limited group of highly specialized expertise,” said Joseph DeVivo, President, Chief Executive Officer and Chairman, Butterfly Network. “We’re proud that this milestone not only extends Butterfly’s commitment to democratizing medical imaging but also marks our first Butterfly Embedded partner to commercialize — bringing our vision to life and demonstrating what Ultrasound-on-Chip can enable beyond traditional ultrasound.”

"One of the strengths of Focalist is the precision and control it gives me, consistently, across different procedures and clinical settings,” said Dr. Jacob Hutchins, anesthesiologist, Minneapolis, MN. “Expanding the ultrasound options available with the system makes that platform even more adaptable across specialties and use cases."  

Mendaera and Butterfly will both be exhibiting at the American College of Emergency Physicians (ACEP26) Scientific Assembly on October 5-7, 2026, in Chicago, Illinois. More information about the new product offering is available by visiting Mendaera at Booth 2318 and Butterfly Network at Booth 2511.

About Mendaera

Mendaera is building a new category of handheld robotics designed to make precision more accessible across healthcare. With its Focalist™ system, which combines real-time imaging and guidance software with intuitive handheld robotic control, Mendaera supports clinicians in delivering consistent, high-quality care across a broad range of minimally invasive procedures and settings.

Based in Silicon Valley, California, the company is backed by leading investors and a leadership team with a track record of successful outcomes, including Auris Health.

Mendaera’s Focalist™ system has FDA clearance in the U.S. to provide guidance for precise instrument placement of common interventional devices by positioning the device relative to the ultrasound transducer and resulting image during diagnostic or therapeutic procedures. The system is intended for use with pediatric and adult patients. The system is used with select compatible FDA-cleared ultrasound probes. Mendaera.com

About Butterfly Network

Butterfly Network, Inc. (NYSE: BFLY) is driving a digital revolution in ultrasound imaging and sensing with its proprietary Ultrasound-on-Chip™ semiconductor technology and software solutions. Butterfly first proved its technology in the point-of-care ultrasound market – commercializing the world's first single-probe, whole-body portable ultrasound device, which is now on its best-selling, third-generation: Butterfly iQ3™. The Company combines its advanced hardware with cloud software and AI, an enterprise workflow solution (Compass AI™) and other offerings to drive adoption of affordable, accessible ultrasound. Butterfly also enables third-party development of imaging AI apps through Butterfly Garden™, its software development kit and AI marketplace.

In addition to its medical imaging products, Butterfly Embedded™ is the Company's Ultrasound-on-Chip™ licensing and co-development business designed to enable a new wave of ultrasound-enabled technologies across non-competitive healthcare markets and beyond. Through Butterfly Embedded™, partners can build and scale novel ultrasound applications powered by Butterfly's proprietary semiconductor chip and software platform.

Butterfly's innovations have been recognized by Prix Galien USA, Fierce 50, TIME's Best Inventions and Fast Company's World Changing Ideas, among other achievements. To learn more, visit: www.butterflynetwork.com.

See the release on Business Wire

‍

Media Contacts:

‍Mendaera Media: 

Michelle Stevens

Media@mendaera.com

‍Butterfly Media:

Andrea Heuer

AOx3 for Butterfly

andrea@12080group.com

917-914-5563

‍Butterfly Investors:

John Doherty

Chief Financial Officer

investors@butterflynetinc.com

‍